{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:45:11Z","timestamp":1785883511499,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["5UG1CA233198-05"],"award-info":[{"award-number":["5UG1CA233198-05"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["5U01CA180888-08"],"award-info":[{"award-number":["5U01CA180888-08"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmoop.2026.107768","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:02:40Z","timestamp":1781010160000},"page":"107768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3412-7689","authenticated-orcid":false,"given":"J.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-2352","authenticated-orcid":false,"given":"Y.","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-0631","authenticated-orcid":false,"given":"P.","family":"DePietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"McFall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"R.","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6379","key":"10.1016\/j.esmoop.2026.107768_bib1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107768_bib2","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1073\/pnas.82.12.4230","article-title":"Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene","volume":"82","author":"Depper","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107768_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ni1584","article-title":"Post-transcriptional control of cytokine production","volume":"9","author":"Anderson","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2026.107768_bib4","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107768_bib5","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.4049\/jimmunol.0900080","article-title":"PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo","volume":"182","author":"Chikuma","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.esmoop.2026.107768_bib6","article-title":"Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Mao","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107768_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107768_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593810","article-title":"Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer","volume":"8","author":"Hardy-Werbin","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107768_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004419","article-title":"Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study","volume":"10","author":"Tannir","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107768_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1984059","article-title":"An open-label, randomized, multi-center study comparing the sequence of high dose aldesleukin (interleukin-2) and ipilimumab (Yervoy) in patients with metastatic melanoma","volume":"10","author":"Hasanov","year":"2021","journal-title":"Oncoimmunology"},{"issue":"30","key":"10.1016\/j.esmoop.2026.107768_bib11","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107768_bib12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107768_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1708065","article-title":"Expression of TIM3\/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1\/PDL1 resistance: implications of immunogram heterogeneity","volume":"9","author":"Kato","year":"2020","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107768_bib14","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/1535-7163.MCT-23-0270","article-title":"Cancer-immunity marker RNA expression levels across gynecologic cancers: implications for immunotherapy","volume":"22","author":"Jou","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107768_bib15","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.62347\/MQFF6404","article-title":"TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer","volume":"14","author":"Ahmed","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107768_bib16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO-25-01453","article-title":"Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 precision oncology study: molecular profiling to match individually dosed, personalized drug combinations","volume":"44","author":"Sicklick","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107768_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","article-title":"Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors","volume":"20","author":"Conroy","year":"2018","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107768_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107768_bib19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107768_bib20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00262-015-1729-x","article-title":"Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry","volume":"64","author":"Santegoets","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmoop.2026.107768_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231220510","article-title":"High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome","volume":"16","author":"Krishnamurthy","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107768_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102942","article-title":"Viewing the immune checkpoint VISTA: landscape and outcomes across cancers","volume":"9","author":"Nishizaki","year":"2024","journal-title":"ESMO Open"},{"issue":"27","key":"10.1016\/j.esmoop.2026.107768_bib23","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107768_bib24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107768_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.24.00511","article-title":"Cyclin-dependent kinase 4\/6 inhibition as a novel therapy for peritoneal mucinous carcinomatosis with GNAS mutations","volume":"43","author":"Weitz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107768_bib26","first-page":"932","article-title":"Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53","volume":"62","author":"Angelo","year":"2002","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107768_bib27","first-page":"2971","article-title":"Autocrine interleukin-1\u03b2 production in leukemia: evidence for the involvement of mutated RAS","volume":"59","author":"Beaupre","year":"1999","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.esmoop.2026.107768_bib28","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1002\/cncr.31724","article-title":"GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers","volume":"124","author":"Parish","year":"2018","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.esmoop.2026.107768_bib29","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1200\/JCO.24.00186","article-title":"Molecular and clinicopathologic impact of GNAS variants across solid tumors","volume":"42","author":"Johannet","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107768_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrc3521","article-title":"The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer","volume":"13","author":"O\u2019Hayre","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"6236","key":"10.1016\/j.esmoop.2026.107768_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/340692a0","article-title":"GTPase inhibiting mutations activate the \u03b1 chain of Gs and stimulate adenylyl cyclase in human pituitary tumours","volume":"340","author":"Landis","year":"1989","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107768_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cei.12629","article-title":"Interleukin-2 treatment reverses effects of cAMP-responsive element modulator \u03b1-over-expressing T cells in autoimmune-prone mice","volume":"181","author":"Ohl","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107768_bib33","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ni855","article-title":"c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation","volume":"3","author":"Naramura","year":"2002","journal-title":"Nat Immunol"},{"issue":"76","key":"10.1016\/j.esmoop.2026.107768_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.276pe38","article-title":"Activation of T cells: releasing the brakes by proteolytic elimination of Cbl-b","volume":"2","author":"Schmitz","year":"2009","journal-title":"Sci Signal"},{"issue":"6766","key":"10.1016\/j.esmoop.2026.107768_bib35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/35003235","article-title":"Cbl-b regulates the CD28 dependence of T-cell activation","volume":"403","author":"Chiang","year":"2000","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.esmoop.2026.107768_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154487","article-title":"Immune dysregulation caused by homozygous mutations in CBLB","volume":"132","author":"Janssen","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107768_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1737368","article-title":"Overproduction of IL-2 by Cbl-b deficient CD4+ T cells provides resistance against regulatory T cells","volume":"9","author":"Han","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2026.107768_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156334","article-title":"Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion","volume":"170","author":"Trujillo-Cirilo","year":"2023","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107768_bib39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/2326-6066.CIR-17-0605","article-title":"Hallmarks of T-cell exit from quiescence","volume":"6","author":"Chapman","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:52:57Z","timestamp":1785880377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926017102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2059702926017102"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107768","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107768"}}